WHO/Europe, EC and ECDC urge eligible groups to get vaccinated or boosted to save lives this autumn and winter
Last year’s autumn and winter seasons were unpredictable. Last winter, the cumulative impacts of influenza, COVID-19, and respiratory syncytial virus or RSV hit the very young and the very old the hardest.
|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
Australian discovery of change in ‘killer T cells’ could help fight against influenza
Research led by Dr Carolien van de Sandt, a senior research fellow at the Doherty Institute and 2023 Claude Hannoun Prize, and UNSW Sydney shows that cells are replaced as we get older by ones less able to read threat from infections
Scientific Papers
News
Article
Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study
Oral Antiviral (OAV) COVID-19 treatments are widely used, but evidence for their effectiveness against the Omicron variant in higher risk, vaccinated individuals is limited.
Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season
WHO convenes technical consultations in February and September each year to recommend viruses for inclusion in influenza vaccines for the northern hemisphere (NH) and southern hemisphere (SH) influenza seasons, respectively.
Vaccine Monitoring Platform research agenda
The Vaccine Monitoring Platform (VMP) is a collaboration between EMA and ECDC for the timely generation of independent real-world evidence (RWE) on the safety and effectiveness of vaccines in use in EU/EEA immunisation programs.
Scientific Papers
Article
News
Factors associated with delayed diagnosis of symptomatic adult COVID-19 cases presenting to primary care: a population-wide study during transition from Delta to Omicron BA.1 in Singapore
During pandemics, avoiding time delay in diagnosing infection is crucial.
Invitation to participate in the second public survey to inform the global research agenda on Public Health and Social Measures
WHO welcomes stakeholders from sectors such as health, education, transportation, agriculture, finance, social services to complete a public survey to identify priorities for a global research agenda on Public Health and Social Measures (PHSM).
A computationally designed antigen eliciting broad humoral responses against SARS-CoV-2 and related sarbecoviruses
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Benefits of ensitrelvir in Covid-19 and long Covid highlighted in two studies
The benefits of ensitrelvir use in patients with symptoms of long Covid and as a second-line treatment option for those hospitalised with Covid-19.
Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases
